sTRBC1 and cyTRBC1 Expression Distinguishes Indolent T-Lymphoblastic Proliferations From T-Lymphoblastic Leukemia/Lymphoma.

Indolent T-lymphoblastic proliferation (iT-LBP) consists of a proliferation of non-neoplastic TdT+ T cells in extrathymic tissues, requiring no treatment. However, due to overlapping clinical and histologic features, distinguishing iT-LBP from T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) can be challenging. Recently, flow cytometry-based evaluation of TRBC1 has been used to detect of T-cell clonality in TCRαβ+ mature T-cell lymphomas and aid in the differential diagnosis between T-ALL and normal thymocytes. We present a case of iT-LBP with high-grade serous ovarian carcinoma (HGSOC). To investigate the potential utility of TRBC1 expression in distinguishing iT-LBP from T-ALL/LBL, we assessed both surface (s) and cytoplasmic (cy) TRBC1 expression patterns on blast cells from the patient with iT-LBP and HGSOC as well as 11 patients diagnosed with T-ALL/LBL. The results revealed that sTRBC1 and cyTRBC1 exhibited polytypic expression patterns in patient with iT-LBP and HGSOC, while cyTRBC1 showed monotypic expression in those with T-ALL/LBL. This suggests that evaluation of sTRBC1 and cyTRBC1 expression can serve as a simple, rapid, and effective approach to differentiate between iT-LBP and T-ALL/LBL.

[1]  Mingyong Li,et al.  Cytoplasmic TRBC1 Expression in T-ALL and AITL. , 2022, American journal of clinical pathology.

[2]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[3]  R. Warnke,et al.  Indolent T‐lymphoblastic proliferation: A systematic review of the literature analyzing the epidemiologic, clinical, and pathologic features of 45 cases , 2022, International journal of laboratory hematology.

[4]  N. Villamor,et al.  High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in Tαβ-Large Granular Lymphocytic Leukemia , 2022, Cancers.

[5]  Xiaoge Zhou,et al.  Indolent T-lymphoblastic proliferation: a report of three cases , 2021, Virchows Archiv.

[6]  N. Villamor,et al.  Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation , 2021, Cancers.

[7]  Ji Yuan,et al.  Flow Cytometric Evaluation of Surface and Cytoplasmic TRBC1 Expression in the Differential Diagnosis of Immature T-Cell Proliferations. , 2021, American journal of clinical pathology.

[8]  M. Loh,et al.  Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma , 2021, Blood Advances.

[9]  U. Johansson,et al.  Emerging Role of T-cell Receptor Constant β Chain-1 (TRBC1) Expression in the Flow Cytometric Diagnosis of T-cell Malignancies , 2021, International journal of molecular sciences.

[10]  F. Craig,et al.  Utility of T-Cell Receptor β Constant Chain-1 Expression in the Diagnosis of Peripheral Blood Involvement by Cutaneous T-Cell Lymphoma. , 2020, The Journal of investigative dermatology.

[11]  D. Jevremovic,et al.  T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics , 2020, Modern Pathology.

[12]  B. Wood,et al.  Flow cytometric features of incidental indolent T lymphoblastic proliferations , 2020, Cytometry. Part B, Clinical cytometry.

[13]  W. Schamel,et al.  αβ and γδ T cell receptors: Similar but different , 2020, Journal of leukocyte biology.

[14]  D. Jevremovic,et al.  Single Antibody Detection of T‐Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T‐Cell Neoplasms and Monotypic Small CD8‐Positive Subsets of Uncertain Significance , 2020, Cytometry. Part B, Clinical cytometry.

[15]  N. Harris,et al.  Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome , 2018, The American journal of surgical pathology.

[16]  A. Bax,et al.  The Role of Molecular Flexibility in Antigen Presentation and T Cell Receptor-Mediated Signaling , 2018, Front. Immunol..

[17]  M. Piris,et al.  Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies , 2017, Nature Medicine.

[18]  R. Warnke,et al.  Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression , 2014, The American journal of surgical pathology.

[19]  R. West,et al.  TdT+ T-lymphoblastic Populations Are Increased in Castleman Disease, in Castleman Disease in Association With Follicular Dendritic Cell Tumors, and in Angioimmunoblastic T-cell Lymphoma , 2012, The American journal of surgical pathology.

[20]  B. Nathwani,et al.  Indolent T-lymphoblastic proliferation: report of a case with a 16-year course without cytotoxic therapy. , 1999, The American journal of surgical pathology.